Leveraging our proprietary technology platforms — Phytopower® Development Platform of Bioactive Molecules & Ingredients from Global Medicinal Plants, Aktinsyn® Technology Platform of Synthetic Chemistry, and Aktinbio® Development Platform of Biotechnology, AKTINPHARM® offers integrated CRDMO services to global pharmaceutical enterprises, biotech companies, and Marketing Authorization Holders (MAHs). Our end-to-end capabilities span drug discovery, API process development, CMC studies, formulation development, regulatory documentation support, and commercial manufacturing.

AKTINPHARM® focuses on natural drugs, small-molecule APIs, peptides, ADC linker-payloads, and oligonucleotide drugs/LNP delivery materials. By embedding rapid early-stage R&D, robust process development, in-depth quality studies, and seamless regulatory compliance throughout the entire product lifecycle, we empower our clients to accelerate their transformation from proof-of-concept to IND/IMPD filings and from clinical supplies to commercial manufacturing.

AKTINPHARM® integrates discovery, process development, analytics, formulation development, regulatory support, and manufacturing into a unified technological pipeline for synchronized advancement. Through flexible FTE and FFS collaboration models, we support full-scale development needs ranging from non-GMP R&D samples to GMP clinical and commercial supply, as well as from lab-scale and pilot-scale up to commercial manufacturing, catering to our clients' differentiated demands for speed, cost and regulatory compliance at varying stages.

AKTINPHARM® CRDMO: Making Complex Molecules More Developable, Making Advanced Therapies More Manufacturable.